Mariam Mailyan, Medical Oncologist at Yeolyan Hematology and Oncology Center, shared a post by Nathan Pennel, Vice Chair of Clinical Research at Cleveland Clinic Taussig Cancer Institute, on LinkedIn:

“The management of EGFR-mutant NSCLC has rapidly progressed in recent years across the stages, leading to enhanced survival results for patients and setting the stage for other oncogene drivers.

Despite these achievements, numerous hurdles persist, such as tailoring treatment recommendations to individuals and enhancing patient selection, preferably employing biomarker-guided methods.

Future research should also assess approaches to reduce treatment side effects to ensure that patients not only survive longer but also experience a better quality of life.”

Quoting Nathan Pennell’s post:

“Excited to share that the first published article in the 2024 American Society of Clinical Oncology (ASCO) Educational Book is online now!”

Source: Mariam Mailyan/LinkedIn and Nathan Pennell/LinkedIn